Ticagrelor for preventing thrombotic events in adults with acute coronary syndromes

Published on 05 Feb 2018
Last Updated on 02 Jan 2019

Guidance Recommendations The Ministry of Health's Drug Advisory Committee has recommended:

• Ticagrelor 90 mg tablet for preventing thrombotic events (cardiovascular death, myocardial infarction and stroke) in adults with acute coronary syndromes, that is, people:

• with ST-segment-elevation myocardial infarction (STEMI); or

  • with non-ST-segment-elevation myocardial infarction (NSTEMI); or

  • with unstable angina requiring hospitalisation—defined as ST or T wave changes on electrocardiogram suggestive of ischaemia plus one of the following characteristics:

    • age 60 years and older;

    • previous myocardial infarction;

    • previous coronary artery bypass grafting (CABG);

    • coronary artery disease with stenosis of 50% or more in at least two vessels;

    • previous ischaemic stroke;

    • previous transient ischaemic attack;

    • carotid stenosis of at least 50%;

    • cerebral revascularisation;

    • diabetes mellitus;

    • peripheral arterial disease; or

    • chronic renal dysfunction, defined as a creatinine clearance of less than 60 ml per minute per 1.73m²of body surface area.

Ticagrelor should be used in combination with low-dose aspirin for up to 12 months.

Subsidy status

Ticagrelor 90 mg tablet is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications. MAF assistance does not apply to the ticagrelor 60 mg tablet.

PES Ticagrelor for preventing thrombotic events in adults with acute coronary syndromes (Published 2 Jan 2019) [PDF, 486 KB] ↗ (opens in new tab)

Ticagrelor for preventing events in adults with ACS (2 Jan 2019) [PDF, 205 KB] ↗ (opens in new tab)